Korea Q4 Roundup: International Growth A Key Factor For Major Firms

Hanmi’s Neutropenia Drug Off To Solid US Start

 
• By Jung Won Shin
  
earnings
Korean Pharmas Sought Business Diversification, Acquisition In 2022 • Source: Shutterstock

More from South Korea

More from Focus On Asia